Last reviewed · How we verify
NCT02259218
Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy
trial testing laboratory biomarker analysis in Adult Brain Tumor in 273 participants. Completed in 17 September 2025.
17 September 2025
Quick facts
| Lead sponsor | Ohio State University Comprehensive Cancer Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 273 |
| Start date | 4 October 2012 |
| Primary completion | 17 September 2025 |
| Estimated completion | 17 September 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- laboratory biomarker analysis — full drug profile →
Conditions studied
- Adult Brain Tumor — all drugs for Adult Brain Tumor →
- Lung Cancer — all drugs for Lung Cancer →
- Radiation Toxicity — all drugs for Radiation Toxicity →
Sponsor
Ohio State University Comprehensive Cancer Center
Who can join
18 and older, any sex, with Adult Brain Tumor or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research trial studies metabolomic and other molecular profiling to identify predictive biomarkers for radiation toxicity and survival in patients with lung or brain cancers receiving radiation therapy. Studying samples of blood, urine, and tissue from patients with lung or brain cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer and predict which patients are at higher risk for developing radiation side effects and how well patients will respond to radiation treatment.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Dexheimer GM, Alves J, Reckziegel L, Lazzaretti G, et al · · 2017 · cited 22× · PMID 29038614 · DOI 10.1155/2017/5472893 -
Epigenomic Echoes-Decoding Genomic and Epigenetic Instability to Distinguish Lung Cancer Types and Predict Relapse.
Baumann AA, Buribayev Z, Wolkenhauer O, Salybekov AA, et al · · 2025 · cited 5× · PMID 39982247 · DOI 10.3390/epigenomes9010005
Verify or expand the search:
- PubMed search for NCT02259218
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of laboratory biomarker analysis
Trials testing the same drug.
- NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma · not yet recruiting
- NCT07411612 — The Association Between Postoperative Inflammatory and Neurological Serum Biomarker Concentrations and Occurrence of Pos · recruiting
- NCT07375433 — Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course a · recruiting
- NCT05388773 — Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cance · Phase 2 · recruiting
- NCT02122172 — Afatinib in Advanced Refractory Urothelial Cancer · Phase 2 · terminated
Other Ohio State University Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT06816979 — Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell · NA · not yet recruiting
- NCT07529483 — Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cysts · Phase 2 · not yet recruiting
- NCT07455513 — A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer · NA · not yet recruiting
- NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting
- NCT07503925 — THRIVE Study: Understanding How Oral Nicotine Pouches Affect Public Health · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02259218 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02259218.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing